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Introduction: The long-term safety and therapeutic response of sodium oxybate (SXB) in fibromyalgia syndrome
(FM) patients were assessed for a combined period of up to 1 year in a prospective, multicenter, open-label, extension
study in patients completing 1 of 2 phase 3 randomized, double-blind, controlled, 14-week trials that examined
the efficacy and safety of SXB 4.5 g, SXB 6 g, and placebo for treatment of FM.
Methods: This extension study comprised an additional 38 weeks of treatment and was carried out at 130 clinical sites
in 7 countries. Initial entry criteria for the previous 2 double-blind clinical trials required that patients aged ≥ 18 years
met the American College of Rheumatology 1990 criteria for FM, had a body mass index (BMI) < 40 kg/m2, and had a
score ≥ 50 on a 100-mm pain visual analog scale (VAS) at baseline. All patients began treatment in the extension
study with SXB 4.5 g/night (administered in 2 equally divided doses) for at least 1 week, followed by possible serial
1.5 g/night dose increases to 9 g/night (maximum) or reductions to 4.5 g/night (minimum).
Results: Of the 560 FM patients enrolled in this extension study, 319 (57.0%) completed the study. The main
reason for early discontinuation was adverse events (AEs; 23.0% of patients). Patients were primarily middle-aged
(mean 46.9 ± 10.8 years), female (91.1%), white (91.4%), with a mean duration of FM symptoms of 9.9 ± 8.7 years.
Serious AEs were experienced by 3.6% of patients. The most frequently reported AEs (incidence ≥ 5% at any dose or
overall) were nausea, headache, dizziness, nasopharyngitis, vomiting, sinusitis, diarrhea, anxiety, insomnia, influenza,
somnolence, upper respiratory tract infection, muscle spasms, urinary tract infection, and gastroenteritis viral.
Maintenance of SXB therapeutic response was demonstrated with continued improvement from controlled-study
baseline in pain VAS, Fibromyalgia Impact Questionnaire (FIQ) total scores, and other measures. Responder analyses
showed that 68.8% of patients achieved ≥ 30% reduction in pain VAS and 69.7% achieved ≥ 30% reduction in FIQ
total score at study endpoint.
Conclusions: The long-term safety profile of SXB in FM patients was similar to that in the previously reported controlled
clinical trials. Improvement in pain and other FM clinical domains was maintained during long-term use.
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Fibromyalgia syndrome (FM) is a multidimensional dis-
order with many clinical manifestations. Consequently,
it has been challenging to characterize its etiology and
to identify a single treatment that addresses all of its
manifestations. The 1990 American College of Rheumatol-
ogy (ACR) criteria for FM focused on chronic widespread
pain and tenderness at 11 or more of 18 tender points
[1]. By design, the recent 2010 ACR diagnostic criteria
integrated widespread pain with other important clinical
domains [2] and abandoned tender-point examination.
The 2010 ACR criteria identify combinations of clinical
features, including chronic widespread pain, sleep dis-
turbance, fatigue, and dyscognition [2-6]. The move to
involve domains other than pain in these criteria is in
line with the 2009 OMERACT (Outcome Measures in
Rheumatoid Arthritis Clinical Trials) international guide-
lines for important research domains in fibromyalgia
studies [7,8], which also included low pain threshold
(allodynia), psychological factors (anxiety and depression)
and physical function. Additionally, OMERACT worked
with physicians and FM patients to develop consensus
regarding core symptom domains that should be assessed
in FM clinical trials, and screening tools have also been
developed with the same methodology [9]. These core
domains include pain, tenderness, sleep disturbance,
fatigue, patient global assessment, and multidimensional
function [7,8].
Only a few medications have demonstrated efficacy
relative to placebo in reducing pain, but none have shown
efficacy across all outcomes including functional impair-
ment, fatigue, sleep disturbance and quality of life (QoL).
The United States (US) Food and Drug Administration
approved pregabalin, duloxetine, and milnacipran for the
treatment of FM [10-12] based on randomized clinical
trials lasting up to six months. Extension studies of all three
drugs have further suggested that long-term tolerability and
efficacy are consistent with that observed in the clinical
trials [13-17]. Amitriptyline has been widely prescribed for
FM and is recommended across existing FM treatment
guidelines [18] but it was never formally evaluated by US
or European Union (EU) regulators for FM. While a
recent meta-analysis suggested that amitriptyline was
superior to duloxetine and milnacipran in improving pain,
sleep disturbances, fatigue and QoL in FM at minimum
dosages of 10 and 50 mg/day, the methodological quality
of the amitriptyline studies was considered poor [19], and
tachyphylaxis has been reported to arise in less than three
months [19,20]. Furthermore, meta-analyses of currently
approved medications have shown only modest efficacy
for pain and have not shown efficacy on other domains
[19,21,22], and population studies have not demonstrated
that FM medications have had any meaningful effect on
outcomes over time [23].Sodium oxybate (SXB) is the sodium salt of γ-hydroxybu-
tyrate (GHB), an endogenous metabolite of γ-aminobutyric
acid (GABA) with central nervous system (CNS) depressant
properties. As an oral solution, SXB (Xyrem®) is approved
in the US, the EU and Canada for treating cataplexy and
various symptoms in patients with narcolepsy [24-26]. SXB
taken orally (Alcover®) is approved in the EU for treatment
of alcohol withdrawal and, as an intravenous adjuvant
(Gamma-OH™, Somsanit®), is also approved as a sedating
anesthetic. Because of its ability to modify sleep in nar-
colepsy, the effects of SXB on sleep physiology have
been studied. SXB increased slow-wave sleep (SWS) and
reduced sleep fragmentation in patients with narcolepsy
[27,28]. A phase 2 study in FM patients reported that
treatment for eight weeks with SXB 4.5 and 6 g/night
decreased rapid eye movement (REM) sleep and improved
morning fatigue, and that the 6-g dose also improved
afternoon, evening, and overall fatigue; reduced wakefulness
after sleep onset; and increased SWS and total non-REM
sleep compared with placebo [29]. In the past few years,
SXB has been evaluated in several placebo-controlled
clinical trials for the treatment of FM [30-33]; however, it
is not approved for this indication in the US, the EU, or in
Canada.
Beneficial effects of SXB in the treatment of FM were
demonstrated in two 14-week, phase 3, multicenter,
placebo-controlled studies with 548 and 573 patients,
respectively [32,33]. In these trials, patients were given
SXB 4.5 or 6 g/night or placebo in two doses (at bedtime
and 2.5 to 4 hours later). SXB was shown to be effective for
two primary clinically relevant efficacy endpoints: pain se-
verity, defined as the proportion of patients achieving ≥30%
reduction on the pain visual analog scale (VAS) from
baseline to week 14; and functionality, defined as the
proportion of patients achieving ≥30% reduction in the
Fibromyalgia Impact Questionnaire (FIQ) total score from
baseline to week 14. A 30% reduction in pain is recom-
mended as a clinically relevant outcome in chronic pain
trials [34], and a 14% change on the FIQ is considered
clinically relevant [35]. Improvements in patient-reported
outcomes of fatigue, patient global impression of change
(PGI-c), 36-item Short Form Health Survey (SF-36)
physical component summary (PCS), and Jenkins Sleep
Scale (for sleep quality) were also demonstrated.
The adverse-event (AE) profiles observed with SXB in
these studies were similar to those reported with SXB in
patients with narcolepsy [24]. There were no deaths, and
the most common AEs in SXB-treated patients, with an
incidence ≥5% and twice that of placebo in both studies,
were nausea, dizziness, vomiting, and anxiety [32,33].
Given the chronic nature of FM, it is important to
evaluate the long-term safety of SXB in patients with FM
and to address questions about the duration of therapeutic
response. The current open-label extension study was
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response of SXB for a combined period of up to one year
in patients completing the phase 3 placebo-controlled
trials of SXB (14 weeks double-blind plus 38 weeks
open-label extension study treatment) [32,33]. The long-
term effects of SXB on QoL and daytime fatigue in patients
with FM were also assessed.
Methods
Study design and patient selection
This prospective, multicenter, open-label extension study
of SXB for the treatment of FM was carried out at 130
sites (106 sites in the US, 7 in Germany, 6 in France, 6
in Spain, 3 in the United Kingdom, and 1 each in The
Netherlands and Italy) between January 2007 and January
2010. The study was approved by the following institutional
review boards (IRBs) or ethics committees: Quorum Review
IRB (Seattle, WA, USA); The University of Texas Health
Science Center IRB (San Antonio, TX, USA), Western IRB
(Olympia, WA, USA), Research Development and Admin-
istration IRB (Portland, OR, USA), Riverside Research Eth-
ics Committee (London, UK), Hospital General Gregorio
Marañón Ethics Committee (Madrid, Spain), Bayerische
Landesärztekammer Ethics Committee (Munich, Germany),
Azienda Ospedaliero-Universitaria Pisana Ethics Committee
(Rome, Italy), Medisch Spectrum Twente Ethics Committee
(Enschede, The Netherlands), and Hôpital Hôtel-Dieu
Ethics Committee (Paris, France). Each patient provided
informed consent prior to study initiation. The study was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice Guidelines.
Patients with FM who completed either of the two
phase 3, placebo-controlled, double-blind, 14-week trials
(studies 06–008 [32] and 06–009 [33]) evaluating the
efficacy and safety of SXB 4.5 g/night and SXB 6 g/night
were eligible to enroll in this open-label extension study
designed to assess the long-term safety and maintenance
of efficacy of SXB. Within seven days of completing the
phase 3 double-blind clinical trial, patients were enrolled
in the extension study to receive up to 38 additional weeks
of treatment, followed by two weeks of post-treatment
follow-up. The total combined duration of treatment
(double-blind phase and open-label extension) was up to
52 weeks. For consistency in this analysis, weeks of therapy
are numbered to reflect the total combined exposure:
weeks 1 to 14 were the phase 3 double-blind period,
and ‘baseline’ refers to the baseline at the start of the
double-blind period.
Treatments
Regardless of their prior allocation and SXB dose during
phase 3 double-blind treatment, all patients entering the
long-term extension were initiated on SXB 4.5 g/night,
administered in two equally divided doses and remainedat that dose level for at least one week. Subsequent dosage
increases to achieve therapeutic response were permitted
in increments of 1.5 g/night at intervals of at least one
week, to a maximum dose of SXB 9 g/night. Dosage
reductions to address safety and tolerability were permitted
in multiples of 1.5 g/night at intervals of any duration, to
a minimum dose of SXB 4.5 g/night. Patients unable to
tolerate SXB 4.5 g/night were discontinued from the study.
Individual dose titration was based on the investigator’s
impression of clinical effect and tolerability.
Safety evaluations
The safety population consisted of all patients who re-
ceived at least one dose of SXB. Safety was assessed by the
incidence of AEs including serious AEs (SAEs), clinical
laboratory values, suicidality and depression assessments,
electrocardiograms, vital signs and physical examination
findings, including body weight. All observed or spontan-
eously reported treatment-emergent AEs were assessed
by prespecified criteria for severity and seriousness, and
recorded, along with findings from physical examinations,
including vital signs and a 12-lead electrocardiogram
(obtained at week 52 of the combined double-blind and
extension periods). AEs were coded by the Medical Dic-
tionary for Regulatory Activities (MedDRA, Version 9.1).
To assess risk of suicidality and occurrence of major
depression, portions of the Mini-International Neuro-
psychiatric Interview (MINI) [36] were administered at
prespecified time points, as was the Beck Depression
Inventory version II (BDI-II) [37], in accordance with rec-
ommendations from IMMPACT (Initiatives on Methods,
Measurement, and Pain Assessment in Clinical Trials) [34].
Clinical evaluations
Clinical evaluations included overall pain severity, assessed
by a pain VAS, and fatigue, also assessed by a VAS; both
were administered every evening in an electronic diary.
The VAS was a 5-cm line, with measurements converted
to the equivalent of a 100-mm VAS for analysis (0 = no
pain/fatigue to 100 = worst imaginable pain/fatigue). The
mean changes in VAS scores from double-blind baseline
values for pain and fatigue were determined weekly in
the extension study from weeks 14 to 26, and monthly
from weeks 30 to 50; week 52 was also assessed. The
proportions of patients who achieved ≥30% and ≥50%
reductions in overall pain VAS from baseline to extension-
study endpoint were also determined in accordance with
recommendations for chronic-pain trials [34]. The FIQ
[38], PGI-c, and clinical global impression of change
(CGI-c) [39] were performed at weeks 16, 18 and 22, and
at the monthly visits during weeks 26 to 52. The FIQ,
which is a patient self-report questionnaire that evaluates
the impact of FM on daily life, has 10 subscales (physical
impairment, did not feel good, work missed, difficulty with
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and depression). The score for each subscale ranges from 0
to 10. An FIQ total score is the sum of the scores from the
10 subscales and it ranges from 0 to 100, with higher
scores indicating greater impact of FM on functioning;
a decrease in score demonstrates improvement. The pro-
portion of patients who achieved ≥30% reduction in FIQ
total score from double-blind baseline to extension-study
endpoint was also determined. The PGI-c asked patients
to rate their FM since they started blinded SXB treatment
on a 7-point scale (very much better, much better, a little
better, no change, a little worse, much worse, and very
much worse); thus, there was no baseline assessment for
this endpoint. Responders for PGI-c were characterized by
the proportion of patients who reported their FM as ‘very
much better’ or ‘much better.’ The CGI-c was the investi-
gator’s assessment of change from baseline in the patient’s
overall FM condition; the CGI-c was analyzed as the
proportion of patients rated by the investigator as ‘very
much improved’ or ‘much improved.’ The SF-36 [40]
assessed the patient’s QoL at weeks 18, 38, and 52; an
increase in score indicates improvement. Specifically,
physical functioning was assessed using the SF-36 PCS
score, a prespecified secondary endpoint in the double-
blind studies. The mental component summary (MCS) of
the SF-36 was also evaluated.
The proportion of patients meeting composite response
measures was also determined. The FM Syndrome
Composite Response was predefined as the proportion
of patients who achieved ≥30% reduction in pain VAS,
a PGI-c response of ‘much better’ or ‘very much better,’
and ≥30% reduction in FIQ total score. The FM Pain
Composite Response was the proportion of patients
who achieved ≥30% reduction in pain VAS and a PGI-c
response of ‘much better’ or ‘very much better.’
Changes from double-blind baseline in the FIQ ‘tired
upon awakening’ subscale and in the Functional Outcomes
of Sleep Questionnaire (FOSQ) [41] were determined at
extension-study endpoint. The FOSQ is a patient-reported
questionnaire that evaluates the effects of excessive
sleepiness on daytime functioning; lower scores indicate
greater difficulty in daily functioning.
Statistical analysis
All data were summarized using descriptive statistics.
Analyses of changes in safety and efficacy parameters were
relative to the double-blind baseline, with study endpoint
defined as the last available data at extension-study
completion (week 52) or early discontinuation.
Data in summary tables (except AEs) are presented by
final dose in the extension study; the final dose was defined
as the last dose prescribed for the patient by the investiga-
tor. Data in AE summary tables are presented by the last
dose taken at the time of event onset.Results
Patient disposition and baseline demographics
Of the 710 patients who completed double-blind treatment,
561 patients (79%) were assessed for eligibility in the long-
term open-label extension study, and 560 patients were
treated (Figure 1); one patient was not entered into the
extension trial because of a positive test for cannabinoids
on the drugs of abuse screen. The percentages of patients
who entered the long-term extension from each of the two
controlled studies were similar (81% for Study 06–008 and
78% for Study 06–009).
Overall, 319 (57%) patients completed the study, includ-
ing 51% of those who had taken placebo and 60% of
those who had taken SXB during the double-blind period.
The most common reasons for discontinuation were AEs
(23%, including non–treatment-emergent and treatment-
emergent AEs), lack of efficacy (7%), withdrawal of consent
(6%), and lost to follow-up (3%; Figure 1). The mean length
of exposure was 198.9 nights.
Figure 2 is a Kaplan-Meier survival curve of patient
retention throughout all phases of the study and presents
final retention rates with respect to participants who were
randomized to each of the treatment groups during the
double-blind phase as well as for subjects who subse-
quently enrolled in the open-label extension. As shown,
extension study discontinuations were greater among
patients who had been randomized to placebo in the parent
study and were SXB-naïve prior to the extension, with these
discontinuations mainly due to AEs and lack of efficacy.
Patients were predominantly female (91.1%) and white
(91.4%), with a mean ± standard deviation (SD) age of
46.9 ± 10.8 years and mean ± SD body mass index (BMI)
of 28.4 ± 4.6 kg/m2. The mean ± SD duration of FM symp-
toms was 9.9 ± 8.7 years (Table 1), and nearly all patients
(97.5%) had received treatment for FM prior to their
participation in the double-blind studies.
Double-blind baseline values for patients who entered
the extension study indicated the presence of moderate to
severe pain (mean ± SD pain VAS of 72.0 ± 13.3) and fatigue
(mean ± SD fatigue VAS of 73.1 ± 14.8), and impaired
functionality in daily living (mean ± SD FIQ total score of
62.4 ± 14.1; Table 1).
Long-term safety
No deaths occurred during the study. Overall, 498 of 560
(88.9%) treated patients reported at least one treatment-
emergent AE. The overall incidences of AEs for the SXB
4.5-g, 6-g, 7.5-g and 9-g dose groups were 54.1%, 61.3%,
68.2% and 78.6%, respectively (Table 2). The most fre-
quently reported AEs (incidence ≥5% at any dose or
overall) were nausea, headache, dizziness, nasopharyngitis,
vomiting, sinusitis, diarrhea, anxiety, insomnia, influenza,
somnolence, upper respiratory tract infection, muscle
spasms, urinary tract infection and gastroenteritis viral
Study 06-008
Assessed for Eligibility: n =1853
SXB PBO Total
Randomized 365 183 548
Discontinued 142 72 214
39% 39% 39%
Adverse Events 21% 11% 18%
Lack of Efficacy   7% 16% 10%
Withdrew Consent   7%   6%   7%
Other   4%   6%   5%
Study 06-009
Assessed for Eligibility: n =1544
SXB PBO Total
Randomized 385 188 573
Discontinued 140 57 197
36% 30% 34%
Adverse Events 18%   6% 14%
Lack of Efficacy 10% 12% 10%
Withdrew Consent   3%   3%   3%
Other   5%   9%   6%
Completed 223 111 334
61% 61% 61%
Enrolled in 06-010* 183 86 269
82% 77% 81%
Completed 245 131 376
64% 70% 66%
Enrolled in 06-010* 191 101 292
78% 77% 78%
Study 06-010
Assessed for Eligibility*: n = 561 (79%)
Prior Study Treatment
SXB PBO Total*
Treated 374 186 560 (79%)
Prior Study Treatment
SXB PBO Total
Discontinued 150 91 241
40% 49% 43%
Adverse Events 21% 27% 23%
Lack of Efficacy   6%   9%   7%
Withdrew Consent   7%   6%   6%
Lost to Follow-up   3%   2%   3%
Investigator Decision   2%   1%   1%
Protocol Deviation/Violation   1%   1%   1%
Other   1%   1%   1%
Sponsor Decision   0%   2%   1%
Prior Study Treatment
SXB PBO Total
Completed 224 95 319
60% 51% 57%
Figure 1 Disposition of patients. Studies 06–008 and 06–009 were concurrent phase 3, double-blind, placebo-controlled, clinical trials; 06–010
is the open-label extension of the phase 3 trials. The denominator for studies 06–008 and 06–009 is the number of randomized patients, and the
denominator for 06–010 is the number of treated patients. *Denominator is the number of completed patients from 06–008/06–009. PBO,
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Figure 2 Kaplan-Meier survival curve of subjects in studies 06–008
and 06–009 pooled, stratified, and summarized by double-blind
treatment group and sequentially linked with data from subjects
continuing into the open-label extension.
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as mild or moderate in all dose groups. The proportion of
patients who discontinued due to a treatment-emergent
AE was 21.8% (122/560 patients), and the proportions were
similar among the dose groups: 4.5 g, 10.5%; 6 g, 8.3%;
7.5 g, 10.0%; and 9 g, 8.9%. The most frequent treatment-
emergent AEs leading to study discontinuation were
nausea (3.2%), anxiety (2.3%) and dizziness (2.0%). Of
patients who discontinued due to AEs, 55.8% had done
so by the end of month 2 in the extension study.
Twenty (3.6%) patients experienced at least one treat-
ment-emergent SAE: seven (1.3%), five (1.2%), two (0.8%)
and seven (6.3%) patients in the SXB 4.5-g, 6-g, 7.5-g and
9-g groups, respectively (one patient experienced SAEs at
two different doses). These SAEs were single events unless
otherwise noted and included atrial fibrillation; abdominal
pain; upper abdominal pain; gastrointestinal hypomotility;
chest pain in two patients; cholelithiasis in two patients
with chronic cholecystitis in one of those patients and an
additional case of acute cholecystitis; Clostridium difficile
Table 1 Demographic and clinical characteristics of
patients enrolled in the open-label extension
Parameter Value (Number = 560)
Age, years
Mean (SD) 46.9 (10.8)










Mean (SD) 28.4 (4.6)
Range 16.4–41.5
Years since first FM symptoms
Mean (SD) 9.9 (8.7)
Double-blind baseline values, mean (SD)
Pain VAS 72.0 (13.3)
Fatigue VAS 73.1 (14.8)
FIQ total score 62.4 (14.1)
BMI, body mass index; FIQ, Fibromyalgia Impact Questionnaire; FM,
fibromyalgia syndrome; SD, standard deviation; VAS, visual analog scale.
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hospitalization that resulted in Staphylococcal sepsis; limb
injury as a result of an on-the-job accident with a saw
that had no preceding clinical event such as dizziness,
although an ongoing AE of feeling abnormal (‘brain
fog’) was listed; accidental overdose resulting in en-
cephalopathy; cervical spinal stenosis; breast cancer in
situ; mental disorder; somatoform disorder; ovarian cyst;
and chronic obstructive pulmonary disease. Serious AEs
led to study withdrawal in six (1.1%) patients: one (0.2%)
patient each in the SXB 4.5-g and 6-g groups, and 0 and
four (3.6%) patients in the SXB 7.5-g and 9-g groups,
respectively.
Given the pharmacology of SXB and prior clinical ex-
perience, specific AEs of interest are further characterized
below.
Abuse and overdose
Patients with a history of substance abuse were excluded
from the double-blind trials. Detailed review of AE
preferred terms from the open-label extension study did
not identify any terms consistent with abuse, dependence,
or severe withdrawal during treatment. There was one case
of potential misuse in which a patient enrolled at more thanone study site; however, no AEs related to potential abuse
were noted in this patient, and in the entire study, there
was no conclusive evidence of abuse or diversion.
One case of accidental overdose was identified as a SAE
(resulting in transient toxic encephalopathy); a patient who
was advised to take SXB 9 g/night inadvertently took an
extra 4.5 g for a total of 13.5 g for one night. The patient
was hospitalized and use of the study drug was interrupted
for one week, after which the patient resumed treatment
and completed the study without further incident.
Suicidality
Patients were excluded from the double-blind trials for
suicidality and major depression. There were no suicides
or suicide attempts in the open-label extension; a review of
AE verbatim terms, tables, and listings coded by MedDRA
preferred terms, and patient-diary data identified no terms
consistent with AEs related to suicidal ideation or behavior.
Data from the MINI suicidality module and the BDI-II
questionnaire indicated 11 patients who showed some level
of suicide risk, none of which involved suicidal behavior
or resulted in self-harm. Of those 11 patients, one was
discontinued for a protocol violation (history of suicidality)
with no other findings of potential suicidality during
the trial; one was discontinued for depression but was not
listed as current for either suicide risk or major depressive
episode at the safety follow-up visit; one was discontinued
due to rheumatoid arthritis, which developed during
the double-blind period; two withdrew consent; and six
completed the study.
Depression
Depression, considered mild or moderate in severity, was
identified in 24 (4.3%) patients and led to study withdrawal
in 10 patients, dose reduction in two patients and transient
treatment interruption in one patient. Adjustment disorder,
major depression and depressed mood were reported in 10
(1.8%) patients and were considered mild or moderate in
severity. Adjustment disorder led to study withdrawal in
one patient and to SXB dose reduction in another patient.
Findings either on the MINI for major depression or
severe depressive symptoms on the BDI-II were reported
as AEs in 16 patients. Overall mean BDI-II depression
scores were decreased from baseline at all time points, and
the overall percentages of patients with BDI-II scores >13
(indicative of more than minimal depressive symptoms)
decreased relative to baseline (32.7% at baseline versus
16.3% at study endpoint and 12.0% at final follow-up visit;
Table 3).
Respiratory adverse events including
sleep-disordered breathing
The most commonly reported AE possibly related to
respiratory depression was dyspnea, which was reported
Table 2 Most frequent treatment-emergent AEs by dose at time of AE onset in safety population
AE Sodium oxybate dose at event onseta
4.5 g (n = 545) 6 g (n = 432) 7.5 g (n = 239) 9 g (n = 112) Total (N = 560)b
Any AE, number (%)c 295 (54.1) 265 (61.3) 163 (68.2) 88 (78.6) 498 (88.9)
Nausea 44 (8.1) 44 (10.2) 23 (9.6) 10 (8.9) 112 (20.0)
Headache 42 (7.7) 43 (10.0) 21 (8.8) 7 (6.3) 106 (18.9)
Dizziness 29 (5.3) 28 (6.5) 13 (5.4) 6 (5.4) 72 (12.9)
Nasopharyngitis 25 (4.6) 21 (4.9) 7 (2.9) 6 (5.4) 57 (10.2)
Vomiting 21 (3.9) 16 (3.7) 9 (3.8) 7 (6.3) 52 (9.3)
Sinusitis 14 (2.6) 21 (4.9) 13 (5.4) 4 (3.6) 50 (8.9)
Diarrhea 16 (2.9) 24 (5.6) 7 (2.9) 4 (3.6) 49 (8.8)
Anxiety 18 (3.3) 18 (4.2) 11 (4.6) 3 (2.7) 44 (7.9)
Insomnia 12 (2.2) 14 (3.2) 10 (4.2) 3 (2.7) 38 (6.8)
Influenza 12 (2.2) 14 (3.2) 9 (3.8) 3 (2.7) 37 (6.6)
Somnolence 10 (1.8) 15 (3.5) 4 (1.7) 7 (6.3) 34 (6.1)
Upper respiratory tract infection 2 (0.4) 18 (4.2) 11 (4.6) 4 (3.6) 34 (6.1)
Muscle spasms 7 (1.3) 8 (1.9) 10 (4.2) 4 (3.6) 29 (5.2)
Urinary tract infection 5 (0.9) 8 (1.9) 5 (2.1) 6 (5.4) 22 (3.9)
Gastroenteritis viral 1 (0.2) 4 (0.9) 5 (2.1) 6 (5.4) 16 (2.9)
‘Most frequent’ is defined as ≥5% in any dose group or overall. aAll patients began treatment in the long-term extension study with SXB 4.5 g/night and remained
at that dose level for at least one week, with subsequent dose adjustments to address the level of response as well as safety and tolerability as stated in ‘Methods;’
bif the dose at AE onset was not among the indicated doses, the patient was summarized in the ‘Total’ group only; cvalues of Any AE, (number and percent) may
not match the sum of the listed individual events since uncommon events are not included. AE, adverse event.
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severity was reported in one (0.2%) patient. A diagnosis of
sleep apnea in the absence of stable continuous positive
airway pressure therapy was an exclusion criterion, as was
an increased risk of sleep apnea that occurred during the
double-blind studies.
No report of sleep-disordered breathing led to study
withdrawal. Events of apnea, respiratory rate decreased
and respiratory depression led to SXB dose reduction in
two, one, and one patients, respectively. There were no
reports of cyanosis or hypoventilation.Table 3 Beck Depression Inventory version II (BDI-II)
scores at baseline and endpoint
Baseline Endpoint
Number 559 557
Mean BDI-II score (SD) 11.1 (8.15) 5.8 (7.03)
Median BDI-II score 10.0 3.0
Range in BDI-II score 0 to 56 0 to 40
BDI-II severity (score)
Minimal (0 to 13), number (%) 376 (67.3) 466 (83.7)
Mild (14 to 19), number (%) 97 (17.4) 62 (11.1)
Moderate (20 to 28), number (%) 67 (12.0) 21 (3.8)
Severe (29 to 63), number (%) 19 (3.4) 8 (1.4)
SD, standard deviation.Sedation
The most common AE potentially related to CNS depres-
sion was daytime somnolence, which occurred in 34 (6.1%)
patients (43 events) and was of mild or moderate severity.
Somnolence led to study withdrawal in five patients
and to dose reduction in 18 of the 43 events. Sedation,
decreased level of consciousness, hypersomnia and hang-
over occurred in seven (1.3%), three (0.5%), two (0.4%) and
one (0.2%) patients, respectively. Hypersomnia led to study
withdrawal in one patient and to SXB dose reduction in
another patient. Sedation and a lower level of conscious-
ness each led to study withdrawal in one patient. (See also
‘Falls, syncope, and accidents’ below.)
Sleepwalking
Sleepwalking occurred in five (0.9%) patients; it was graded
as severe but not serious in one patient and led to SXB
dose reduction in two patients and study withdrawal in two
patients. No sleepwalking-associated injuries were reported.
Falls, syncope, and accidents
Twenty (3.6%) patients had falls (potentially related to a
hangover effect or to the underlying FM), which led to two
study withdrawals and two patients with dose reductions.
Three (0.5%) patients were involved in road traffic acci-
dents, and two (0.4%) were involved in non-traffic acci-
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Figure 4 Maintenance of sodium oxybate therapeutic response
in open-label extension study for patients with at least
12 months of sodium oxybate exposure (n = 210). *SF-36 PCS is
reported for weeks 14, 18, 38 and 42. FIQ, Fibromyalgia Impact
Questionnaire; SEM, standard error of the mean; SF-36 PCS, 36-item
short-form health survey physical component summary; VAS, visual
analog scale.
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and neither of the two non-traffic accidents was related
to treatment. Three patients (0.5%) had syncope, and
one (0.2%) had vasovagal syncope resulting in a fall.
Weight changes
A trend for decreased body weight was observed. For
patients on SXB during the double-blind phase, the mean
body weight continued to decline from baseline to approxi-
mately −5% by week 52 (Figure 3). A parallel reduction in
body weight was observed for patients who had previously
received placebo and then initiated SXB during the exten-
sion. AEs related to weight loss (decreased weight, anorexia
and decreased appetite) were reported in 43 (7.7%)
patients. AEs related to loss of weight were severe in one
(0.2%) patient, led to SXB dose reduction in five (0.9%) pa-
tients and led to study withdrawal in four (0.7%) patients.
AEs related to weight gain were less frequent; there was
increased weight in two (0.4%) patients not accompanied
by edema and increased appetite in one (0.2%) patient.
Maintenance of treatment response
For patients with at least 12 months of SXB exposure
(receiving active treatment in double-blind and open-label
extension study periods combined, n = 210), the mean
improvements from baseline observed at the end of the
double-blind period (14 weeks) were maintained over the
duration of the long-term extension for pain VAS, fatigue
VAS, FIQ total score and SF-36 PCS (Figure 4). The mean
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Figure 3 Mean weight change from baseline for patients who
entered the OLE study, by prior double-blind phase 3 study
treatment. 06–010 is the OLE of the DB phase 3 trials (placebo
patients in the DB phase were initiated on active treatment at the
start of the OLE phase). DB, double-blind; OLE, open-label extension;
SEM, standard error of the mean; SXB, sodium oxybate.controlled study) and from the same controlled-study
baseline to week 52 (end of the open-label extension study),
respectively, were as follows: for the pain VAS, −37.2
and −42.5; for the FIQ total score, −32.6 and −37.9; and for
the fatigue VAS, −37.9 and −42.3, demonstrating mainten-
ance of effect. The mean changes from controlled-study
baseline for SF-36 PCS were 10.3, 10.9, 12.1 and 13.1
points at weeks 14, 18, 38 and 52, respectively, also demon-
strating maintenance of effect; changes from baseline in
the MCS were minimal at all time points (data not shown).
For all treated patients in the long-term extension
study, responder analyses showed that 68.8% and 53.0%
achieved ≥30% and ≥50% reduction in the pain VAS at
extension-study endpoint, respectively (relative to con-
trolled-study baseline), and similar proportions achieved
reductions ≥30% (69.7%) and ≥50% (52.3%) in FIQ total
score (Table 4). At extension-study endpoint, 60.4% of
patients responded with PGI-c responses of ‘very much
better’ or ‘much better’ and investigators considered 63.2%
of the patients ‘very much improved’ or ‘much improved’
in CGI-c scores (Table 4). Approximately half (50.3%)
of the patients were responders in the FM Syndrome
Composite Response, and 52.4% of patients were responders
in the FM Pain Composite Response at the extension-
study endpoint (Table 4).
Reduction in morning tiredness (FIQ ‘tired upon
awakening’ subscale) and improvement in daytime func-
tion related to sleep (FOSQ total score) were seen across
all doses (Table 5).
Discussion
Long-term tolerability and efficacy in FM have been
observed in clinical trials with pregabalin, duloxetine, and
milnacipran [13-17]. Results from this study similarly pro-
vide evidence for the tolerability of SXB during exposure
Table 4 Responder analyses at open-label study endpoint in patients with FM syndrome
Parameter Sodium oxybate final dose
4.5 g 6 g 7.5 g 9 g Totala
Pain VAS number = 165 number = 187 number = 114 number = 81 number = 551
≥30% reduction, number (%) 112 (67.9) 140 (74.9) 67 (58.8) 59 (72.8) 379 (68.8)
≥50% reduction, number (%) 88 (53.3) 110 (58.8) 47 (41.2) 47 (58.0) 292 (53.0)
FIQ total score number = 168 number = 187 number = 114 number = 81 number = 554
≥30% reduction, number (%) 113 (67.3) 142 (75.9) 67 (58.8) 61 (75.3) 386 (69.7)
≥50% reduction, number (%) 81 (48.2) 110 (58.8) 51 (44.7) 47 (58.0) 290 (52.3)
PGI-c number = 167 number = 187 number = 114 number = 81 number = 553
’Very much better’ or ‘much better,’ number (%) 103 (61.7) 117 (62.6) 59 (51.8) 53 (65.4) 334 (60.4)
CGI-c number = 168 number = 187 number = 114 number = 81 number = 554
‘Very much improved’ or ‘much improved,’ number (%) 106 (63.1) 120 (64.2) 66 (57.9) 56 (69.1) 350 (63.2)
FM Syndrome Composite Response number = 167 number = 187 number = 114 number = 81 number = 553
Responders, number (%)b 79 (47.3) 104 (55.6) 48 (42.1) 46 (56.8) 278 (50.3)
FM Pain Composite Response number = 167 number = 187 number = 114 number = 81 number = 553
Responders, number (%)c 85 (50.9) 107 (57.2) 50 (43.9) 47 (58.0) 290 (52.4)
For Pain VAS, baseline was the average of all available daily averages during the last week of the baseline period in the double-blind studies. For post-baseline as-
sessments, the average of all daily averages during the prior week was used. Study endpoint was defined as the last available data (study completion or early dis-
continuation). aIf the final dose was not among those indicated, the patient was summarized only for the ‘Total’ group; bFibromyalgia Syndrome Composite
Responders were patients who achieved PGI-c response of ‘very much better’ or ‘much better,’ ≥30% reduction in pain VAS, and ≥30% reduction in FIQ total score
at study endpoint compared with baseline of the double-blind study; cFibromyalgia Pain Composite Responders (at endpoint) were patients who achieved PGI-c
response of ‘very much better’ or ‘much better’ and who had ≥30% reduction in pain VAS at study endpoint compared with baseline of the double-blind study.
CGI-c, Clinical Global Impression of Change; FIQ, Fibromyalgia Impact Questionnaire; FM, fibromyalgia syndrome; PGI-c, Patient Global Impression of Change; VAS,
visual analog scale.
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improvements in pain and other FM symptoms during
that period. Of the 560 patients who entered the extension
after completing either of the two phase 3 double-blind
studies, 402 (71.8%) patients were treated for at least six
months, and 210 (37.5%) patients received treatment for
at least one year; more than half (57%) of the patients who
were enrolled completed the study.Table 5 Change from baseline at open-label study endpoint i
Parameter
4.5 g 6
FIQ subscale: ‘tired upon awakening’
Baseline, number 172 18
Mean (SD) 7.93 (1.77) 8.19 (
Endpoint, number 168 18
Mean change (SE) −4.16 (0.25) −4.56
FOSQ total score
Baseline, number 162 18
Mean (SD) 14.00 (3.82) 13.73
Endpoint, number 157 18
Mean change (SE) 2.75 (0.30) 3.19 (
Study endpoint was defined as the last available data (study completion or early di
was summarized only for the ‘Total’ group. FIQ, Fibromyalgia Impact Questionnaire;
SE, standard error.There were no deaths in this study. While SAEs were
reported in 20 (3.6%) patients and led to discontinuation
in six of these individuals, only three SAEs in two patients
were considered related to treatment: accidental overdose,
transient toxic encephalopathy (resulting from the acciden-
tal overdose) and gastrointestinal hypomotility. The most
frequently reported AEs were similar to those observed in
previous studies of SXB in patients with narcolepsy [24]n FIQ ‘tired upon awakening’ subscale and FOSQ
Sodium oxybate final dose
g 7.5 g 9 g Totala
8 114 81 559
1.74) 8.35 (1.69) 8.57 (1.48) 8.21 (1.71)
7 114 81 554
(0.22) −3.84 (0.31) −4.88 (0.34) −4.33 (0.13)
2 114 79 541
(3.60) 13.20 (3.61) 12.76 (3.74) 13.56 (3.71)
1 114 79 535
0.27) 3.28 (0.37) 3.82 (0.42) 3.15 (0.16)
scontinuation). aIf the final dose was not among those indicated, the patient
FOSQ, Functional Outcomes of Sleep Questionnaire; SD, standard deviation;
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the AEs most often resulting in study discontinuation.
There appeared to be a linear dose response for overall
AEs, but not for individual AEs, although evaluation of
a dose–response relationship for particular AEs was
precluded by the open-label design and the allowance of
flexible dosing throughout the study. However, the 9-g dose
was associated with a higher incidence of nasopharyngitis,
vomiting, somnolence, urinary tract infection and gastro-
enteritis, but there was no consistent pattern indicating
that the incidence of these AEs was associated with in-
creased doses. It should also be noted that compared with
other dosage groups, the number of exposures to 9 g was
lowest of all allowed dosages in the study. No abuse-
related issues or signals of diversion were observed in the
current study, consistent with the low levels of diversion,
abuse and dependence that have been reported with use
of prescribed SXB [42].
Signs of suicidality and major depression were monitored
closely, especially since FM patients have been reported to
have a higher prevalence of major depression than the
general population [43,44], as well as an increased risk of
suicide [45-47]. However, in this study, there was no sign
of increased suicidality in patients receiving long-term
SXB. Additionally, no risk of increased depression was
detected and, although depression was not formally
evaluated as an outcome, it should be noted that relative
to baseline, mean BDI-II scores improved, and a smaller
proportion of patients at endpoint reported depression
that was greater than ‘minimal depression’ on the BDI-II.
Treatment with SXB was associated with a mean weight
loss, consistent with what has been observed with SXB in
a retrospective chart review of patients with narcolepsy
[48]. Weight loss was reported as an AE in 3.8% of
patients, with one event of decreased weight graded as
severe. Of note, the mean baseline BMI for patients
enrolled in this study was 28.4 kg/m2, a level considered
pre-obese [49].
With respect to therapeutic response, SXB provided
clinically important improvements over the study duration
across multiple FM domains identified as important by
OMERACT, including pain, functioning, fatigue and
tiredness. Both patient- and investigator-rated overall
well-being assessments at the end of the study indicated
long-term improvement. Importantly, not only did 68.8%
of patients achieve ≥30% reduction in pain compared with
baseline, a clinically meaningful level of pain relief [50],
but more than half (53.0%) of the patients achieved ≥50%
reduction, which is considered a substantial decrease in
pain [34].
The pain, fatigue, sleep-related and functional benefits
were also supported by substantial improvements on the
FIQ, with proportions of patients achieving the 30% and
50% thresholds similar to those observed for pain. Forperspective, note that a smaller (14%) change on the FIQ
has been shown to represent the minimal clinically im-
portant difference [35]. The robustness of the response
across individual outcomes was also reflected by the high
proportions of patients who achieved the FM Syndrome
Composite Response (50.3%) and the Fibromyalgia Pain
Composite Response (52.4%). Composite measures, which
represent a conservative assessment of response since
they require that patients fulfill two or more criteria to be
considered responders, have been reported only in clinical
FM trials of milnacipran [51-55] and SXB [30,32,33].
Several limitations of this study should be noted in-
cluding lack of a placebo group since this was an open-
label study. Common to such extension studies, patients
remaining in the study generally represent a self-selected
population of those who both tolerated the drug and
achieved efficacy. Furthermore, this study used populations
from previous clinical trials, which were restricted by
specific inclusion and exclusion criteria. For both of these
reasons, the results may not be fully generalizable to the
clinical setting.
An additional limitation is that the overall discontinu-
ation rate of 43% does not enable a true assessment of
efficacy in all patients at the one-year time point. However,
applying a worst-case scenario in which discontinued
patients are assumed to be non-responders (that is, did
not achieve ≥30% reduction in pain VAS) still suggests a
substantial treatment benefit, with a responder rate at
endpoint of 45.7%. Thus, it should be considered that the
true response is likely to fall between this estimate and the
68.8% reported. It should also be noted that the overall
discontinuation rate was consistent with those seen in
other FM open-label extension studies [13,14,16]. The
7% discontinuations due to lack of efficacy suggests that
the therapeutic effect that was maintained over the long-
term and over multiple efficacy endpoints was clinically
meaningful in the patients who tolerated the drug.
Overall, the long-term study results support those from
the phase 2 and phase 3 controlled clinical trials [30-33]
in demonstrating a similar safety profile; similar improve-
ments across multiple clinically meaningful FM domains
were observed and maintained throughout the duration of
the study. The demonstrated long-term effectiveness of
SXB in FM should be viewed in light of its overall safety
profile and potential risks of its use.
Conclusions
The long-term, open-label (up to 38 weeks) safety profile
of SXB in FM patients was similar to those observed in
the phase 2 and phase 3 double-blind trials. Treatment
with SXB was associated with clinically relevant improve-
ments across multiple FM domains, including pain and
functioning; these improvements were maintained during
long-term treatment (up to 52 weeks). These data support
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http://arthritis-research.com/content/15/6/R185the conclusion that SXB can provide long-term bene-
fits in the multidimensional management of FM. While
multidimensional efficacy is a desired goal of therapy,
any therapeutic benefits should be weighed against other
factors, including individual patient needs as well as
potential risks.
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